Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis.

Schelbergen, R F (author)

Geven, E J (author)

van den Bosch, M H J (author)

Eriksson, H (author)

Leanderson, Tomas (author): Lund University,Lunds universitet,Immunologi,Forskargrupper vid Lunds universitet,Immunology,Lund University Research Groups

Vogl, T (author)

Roth, J (author)

van de Loo, F A J (author)

Koenders, M I (author)

van der Kraan, P M (author)

van den Berg, W B (author)

Blom, A B (author)

van Lent, P L E M (author)

(creator_code:org_t)

2015-05-12
2015
English.
In: Annals of the Rheumatic Diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 74:12, s. 2254-2258

Related links:: http://www.ncbi.nlm....; show more...; http://dx.doi.org/10...; https://lup.lub.lu.s...; https://doi.org/10.1...; show less...

Abstract Subject headings

Alarmins S100A8/A9 regulate pathology in experimental osteoarthritis (OA). Paquinimod is an immunomodulatory compound preventing S100A9 binding to TLR-4. We investigated the effect of paquinimod on experimental OA and human OA synovium.

By the author/editor: Schelbergen, R F; Geven, E J; van den Bosch, M ...; Eriksson, H; Leanderson, Toma ...; Vogl, T; show more...; Roth, J; van de Loo, F A ...; Koenders, M I; van der Kraan, P ...; van den Berg, W ...; Blom, A B; van Lent, P L E ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Rheumatology and ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.